Barclays maintains Insulet at Equal-Weight, raises price target to $165 from $150

Barclays kept Insulet at Equal-Weight but raised its price target to $165 from $150, suggesting a 5.7% upside from the Nov 5 close of $156.12. Recent analyst notes on Insulet have price targets ranging from $167 to $180.

Original reporting
Published Nov 6, 2026, 4:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Insulet at Equal-Weight, raises price target to $165 from $150 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade may attract short‑term buying, pushing the stock closer to $165.

02

Market read

A fresh analyst target increase provides a modest trading catalyst for Insulet.

03

What to watch

Potential regulatory or reimbursement risks not reflected in the new target.

Relevance 7/10Novelty 6/10Timing: immediate

Background

Barclays' analyst note updates its valuation model for Insulet, reflecting recent market dynamics.

Market effects

Higher target may lift other diabetes device peers as the sector gains optimism.

U.S. market focus; limited regional spillover.

Modest; primarily affects Insulet and related med‑tech stocks.

Counterpoint

The target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Barclays

    Equity research firm issuing the price target raise.

  • Insulet

    U.S.-listed medical device maker (ticker PINS).

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.

$PODDHighAI 8/10

What Insulet (PODD) Said on Its Q3 Earnings Call

Insulet (PODD) reported Q3 revenue of $842M, adjusted EPS of $1.99, and record gross margin of 74.2%. The company narrowed its 2026 revenue outlook to 21-22% growth and expects 2027 growth to be modestly below mid-teens. Insulet also announced a $1B increase to its share repurchase program and product updates, including Omnipod 6 and a type 2 diabetes system.